September 2021 tender notification
Pharmac is pleased to provide the latest tender results.
Download the tender notification [PDF 45 KB]
Tender results
PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 October 2021 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2020/21 Tender – Principal Supply Status applies until 30 June 2024
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of subsidy change |
Principal Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Oxycodone hydrochloride |
Inj 10 mg per ml, 1 ml ampoule; 5 ampoule pack |
$7.28 |
$5.82 |
Hameln (Max Health) |
1 February 2022 |
1 July 2022 |
OxyNorm (MundiPharma) |
|
Oxycodone hydrochloride |
Inj 10 mg per ml, 2 ml ampoule; 5 ampoule pack |
$14.36 |
$11.49 |
Hameln (Max Health) |
1 February 2022 |
1 July 2022 |
OxyNorm (MundiPharma) |
|
Oxycodone hydrochloride |
Inj 50 mg per ml, 1 ml ampoule; 5 ampoule pack |
$30.60 |
$22.92 |
Hameln (Max Health) |
1 February 2022 |
1 July 2022 |
OxyNorm (MundiPharma) |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand (Supplier) |
DV Limit |
Listing date |
Principal Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Oxycodone hydrochloride |
Inj 10 mg per ml, 1 ml ampoule; 5 ampoule pack |
$7.28 |
$5.82 |
Hameln (Max Health) |
5% |
1 February 2022 |
1 July 2022 |
OxyNorm (MundiPharma) |
|
Oxycodone hydrochloride |
Inj 10 mg per ml, 2 ml ampoule; 5 ampoule pack |
$14.36 |
$11.49 |
Hameln (Max Health) |
5% |
1 February 2022 |
1 July 2022 |
OxyNorm (MundiPharma) |
|
Oxycodone hydrochloride |
Inj 50 mg per ml, 1 ml ampoule; 5 ampoule pack |
$30.60 |
$22.92 |
Hameln (Max Health) |
5% |
1 February 2022 |
1 July 2022 |
OxyNorm (MundiPharma) |
|
Teicoplanin |
Inj 400 mg vial; 1 vial pack |
$56.50 |
$49.95 |
Targocid (Sanofi) |
5% |
1 January 2022 |
1 June 2022 |
Teicoplanin Mylan (Viatris) |
Tender declines - Products where no tender is to be awarded for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status, Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2018/19 Invitation to Tender, dated 1 November 2018
- the 2019/20 Invitation to Tender, dated 1 November 2019
- the 2020/21 Invitation to Tender, dated 2 November 2020
2018/19 Invitation to Tender
|
Chemical name |
Line item |
|
Teriparatide |
Inj 250 mcg per ml |
2019/20 Invitation to Tender
|
Chemical name |
Line item |
|
Clobazam |
Oral liq |
|
Lamivudine |
Tab 300 mg |
|
Talc |
Dusting Powder BP |
|
Thiamine hydrochloride |
Tab 50 mg |
2020/21 Invitation to Tender
|
Chemical name |
Line item |
|
Atracurium besylate |
Inj 10 mg per ml, 2.5 ml |
|
Atracurium besylate |
Inj 10 mg per ml, 5 ml |
|
Fentanyl |
Inj 10 mcg per ml, 10 ml syringe |
|
Fentanyl |
Inj 20 mcg per ml, 50 ml prefilled syringe |
|
Fentanyl |
Inj 20 mcg per ml, 100 ml bag |
|
Pemetrexed |
Powder for infusion 100 mg |
|
Pemetrexed |
Powder for infusion 500 mg |
For products included in the 2018/19, 2019/20 and 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.